Xylem reports second-quarter results on July 28 with a notable gap between where analysts think the stock is worth and where it actually trades — a gap the print must either close or widen.
The options market has grown more cautious ahead of the release, though not dramatically so. The put/call ratio has climbed to 0.54, roughly one standard deviation above its 20-day average of 0.39 — a modest defensive tilt rather than outright alarm. That shift followed a rough week for the stock, which fell 2.5% over the past five sessions to close at $119.75, even as the one-month picture is more constructive at +8.5%. Borrow conditions offer no meaningful signal either way: availability is extremely loose at over 1,800% — far more shares available to lend than are currently borrowed — and the cost to borrow a negligible 0.51%. Short interest, at 3.7% of the free float, has edged 18% higher over the past month but remains too modest to represent a concentrated bear thesis.
The core tension heading into this print is a 25%-plus gap between the current price and the analyst consensus target of $150. Recent analyst activity has been broadly constructive but with caveats. Jefferies upgraded to Buy in late June, lifting its target to $140. RBC raised its target to $159 just last week. Stifel trimmed marginally to $157 on July 20 while holding its Buy. The bull case centres on Xylem's 80-20 portfolio simplification program, a recent $850 million BOO project win, and mid-teens earnings growth potential across resilient municipal and healthcare end markets. Bears point to cyclical exposure, continued pressure in China, and the risk that near-term simplification actions constrain growth before the benefits arrive. The consensus sits at Hold — nine Hold ratings versus three Outperforms — which tells its own story: the Street sees upside but is not uniformly confident the near-term execution will get there.
Past earnings prints add another layer of context. The last three quarterly reports all resulted in negative one-day reactions, ranging from just under 1% to nearly 6.6% lower. The five-day picture was similarly soft, with the April 2026 print delivering a roughly 5.8% decline over the following week. The forward earnings multiple of around 20x and an EV/EBITDA near 13x leave limited room for disappointment against that backdrop, particularly with BlackRock holding over 10% of shares and Swedbank Robur trimming its position by over 1.5 million shares in the most recent reporting period.
The July 28 print will test whether Xylem's margin trajectory and order momentum are moving fast enough to justify a re-rating toward the analyst consensus — or whether the gap between targets and price reflects a Street that has been consistently too optimistic on the timing of the recovery.
See the live data behind this article on ORTEX.
Open XYL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
